Home/Pipeline/SCD-044

SCD-044

Psoriasis

Phase 2Active

Key Facts

Indication
Psoriasis
Phase
Phase 2
Status
Active
Companies

About Sun Pharmaceutical

Founded in 1983, Sun Pharma has grown through strategic acquisitions and organic expansion to become a $4.5 billion revenue pharmaceutical giant. The company operates manufacturing facilities across India, USA, Canada, Brazil, Mexico and other countries, serving both developed and emerging markets. Sun Pharma is particularly known for its dermatology franchise and complex generics portfolio, with a growing presence in specialty therapeutics and biosimilars.

View full company profile

About SPARC

SPARC is a specialized research and development arm that emerged from Sun Pharmaceutical Industries, concentrating on innovative drug delivery technologies and new molecular entities. The company has built a pipeline of novel formulations and new chemical entities targeting complex therapeutic areas with high unmet medical needs. Its strategic focus includes developing non-infringing, patent-protected products that offer significant clinical advantages over existing treatments. SPARC's valuation reflects its potential to deliver breakthrough innovations through its research platforms.

View full company profile

About SPARC

SPARC is a specialized research and development arm that emerged from Sun Pharmaceutical Industries, concentrating on innovative drug delivery technologies and new molecular entities. The company has built a pipeline of novel formulations and new chemical entities targeting complex therapeutic areas with high unmet medical needs. Its strategic focus includes developing non-infringing, patent-protected products that offer significant clinical advantages over existing treatments. SPARC's valuation reflects its potential to deliver breakthrough innovations through its research platforms.

View full company profile

Other Psoriasis Drugs

DrugCompanyPhase
Taltz (ixekizumab)Eli LillyApproved
Ilumya (tildrakizumab)Sun PharmaceuticalApproved
ItolizumabBioconApproved
SCD-105SPARCPhase 2
IMP731ImmutepPhase 1/Ib
CYPS317FibroBiologicsDiscovery